Beijing Innocare Pharma Tech
Clinical trials sponsored by Beijing Innocare Pharma Tech, explained in plain language.
A Chinese pharmaceutical company developing and commercializing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug ICP-538 tested in healthy people for first time Results expected Sep 2026 (estimated)
- New pill could ease severe psoriasis in just 12 weeks Results expected Oct 2026 (estimated)
- New pill could tame tough eczema without creams Results expected Nov 2026 (estimated)
- New pill could stop the maddening itch of prurigo nodularis Results expected Mar 2027 (estimated)
- New pill could tame skin lupus flares Results expected Mar 2027 (estimated)
-
New hope for tough lymphoma: experimental drug shows promise
Disease control CompletedThis study tested an experimental drug called ICP-022 in 106 adults with mantle cell lymphoma that had come back or stopped responding to prior treatments. The goal was to see if the drug could shrink tumors and to check its safety. The approach focuses on controlling the disease…
Phase 1/2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Promising combo for rare blood cancer shows early potential
Disease control CompletedThis phase 3 trial tested whether adding the targeted drug orelabrutinib to standard chemotherapy (R-CHOP) works better than chemotherapy alone for people with untreated mantle cell lymphoma, a rare blood cancer. Only 3 patients took part, and the study is now complete. Researche…
Phase 3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC